Thermo Fisher Introduces New Solutions for Fast and Sensitive Nucleic Acid Detection

(Waltham, MA; USA) is presenting its dynamic range of products at AACC 2023 that can help laboratories maximize productivity and innovation. In addition, Thermo Fisher is hosting industry-leading workshops where experts will be discussing the company’s latest innovations for preeclampsia testing with its new biomarkers PlGF and sFlt-1 that can help manage preeclampsia and neuroendocrine tumors.

During this session, Thermo Fisher is presenting two new product offers. The first is a new direct RT-qPCR system that can be used to amplify nucleic acid from inhibitor-enriched samples. The latest data demonstrates new reagents and workflow conditions that work best on saliva and serum samples. Second, the company will discuss the new Invitrogen Lyo-ready Bst DNA Polymerase for RT-LAMP isothermal amplification. This best-in-class enzyme demonstrates the highest speed, sensitivity, and resistance to inhibitor performance in LAMP reactions. Together, the Invitrogen Lyo-ready SuperScript IV Reverse Transcriptase and Invitrogen Lyo-ready RNaseOUT RNase Inhibitors offer the fastest solution for pathogen diagnostics using RT-LAMP.

At AACC 2023, Thermo Fisher is offering live demonstrations of its Indiko and Indiko Plus clinical and specialty chemistry analyzers that are easy-to-use, cost-effective, and designed for load-up and walk-away convenience. An intuitive user interface and many automated features help labs manage their daily workflow. These self-contained analyzers have small footprints and fit well in laboratories with space limitations. Thermo Fisher is also demonstrating the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System and Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System. Thermo Fisher is also offering live demonstrations of its new Diomni Enterprise software which combines instruments, assays, and consumables to streamline workflow from samples to clinical results.

Related Links:
Thermo Fisher Scientific Inc.